Patients with chronic lymphocytic leukemia (CLL) unresponsive to fludarabine-based chemotherapy have a poor prognosis. For these patients allogeneic stem cell transplantation (alloSCT) may be a potential curative treatment modality. Several reports have shown that alloSCT following reduced-intensity conditioning (RIC) significantly diminished treatment-related mortality (TRM) while preserving the graft-versus-leukemia (GvL) effect. However, considerable toxicity due to a high incidence of acute graftversus-host disease (GvHD) and extensive chronic GvHD was observed.
1,2 The use of alemtuzumab (anti-CD52) to deplete for donor and recipient T cells as part of the RIC strategy effectively reduces GvHD, while the administration of alemtuzumab with the stem cell graft may also result in a profound anti-CLL effect. Once durable donor engraftment is achieved, adoptive immunotherapy with donor lymphocyte infusion (DLI) can be applied to promote and enhance the GvL effect. 3, 4 We have demonstrated the feasibility of this approach and showed a reduction in both the incidence and the severity of GvHD. 5 Here, we report the result of 12 patients with advanced CLL treated with in vitro T-cell-depleted RIC alloSCT followed by postponed administration of DLI. Patients with progressive CLL after conventional chemotherapy with ages between 18 and 70 years with a human leukocyte antigen (HLA)-identical sibling donor or an HLA-compatible matched unrelated donor (MUD) were eligible for this study. Patient and transplantation characteristics of the 12 enrolled patients are summarized in Table 1 . The conditioning regimen consisted of fludarabine 30 mg/m 2 /day i.v. on days À10 to À6, busulfan 3.2 mg/kg/day i.v. on days À6 and À5 and antithymocyte globulin 10 mg/kg/ day i.v. on days À4 to À1. T-cell depletion of the stem cell product was performed by incubation with 20 mg alemtuzumab for 30 min. No post-transplant GvHD prophylaxis was administered. DLI was anticipated to be administered in all patients. Patients with persistent disease or incomplete donor chimerism at 6 months after alloSCT received 5 Â 10 6 CD3 þ cells/kg. Escalating doses of CD3 þ T cells were administered at 3-6 months intervals in the absence of development of GvHD if mixed chimerism or CLL persisted. The median follow-up was 21 months (range, 7-61 months). Disease response was assessed using National Cancer Institute Working Group (NCI-WG) criteria with the following additions. Complete response (CR) or partial response (PR) required complete or at least 50% clearance of CLL cells from both bone marrow (BM) and peripheral blood (PB) as detected by multicolor flow cytometry Letters to the Editor with sequential gating strategy for CD45-high/SSC-low/CD19-positive B cells to exclude for precursor normal B cells. The sensitivity of this assay was 0.1%. Patients received a median dose of 12.3 Â 10 6 CD34 þ cells/kg (range 7.9-16.5). All patients had sustained neutrophil (40.1 Â 10 9 /l) and platelet recovery (420 Â 10 9 /l) with a median time to engraftment of 12 days. As shown in Table 2 , before administration of DLI no significant GvHD was observed. Only one patient had developed grade I acute GvHD of the skin. Of the 12 patients, one patient did not receive DLI because of infectious complications after alloSCT. The indications for DLI were mixed chimerism (n ¼ 1), mixed chimerism and persistent disease (n ¼ 7) or progressive disease (n ¼ 3). Four patients received one dose of 5 Â 10 6 CD3 þ T cells/kg, two patients received a lower dose (2.5 Â 10 6 CD3 þ T cells/kg) because of a MUD alloSCT. Four patients received two doses and one patient (patient 10) received five doses of DLI with a maximum dose of 1.5 10 8 T cells/kg because of refractory disease. Four patients developed Overall survival (OS), event-free survival (EFS) and treatment-related mortality (TRM) after in vitro T-cell-depleted alloSCT and the administration of DLI. AlloSCT, allogeneic stem cell transplantation; DLI, donor lymphocyte infusion.
Letters to the Editor acute GvHD after DLI (one grade I, two grade II and one grade IV). These four patients developed limited chronic GvHD. Two patients died of infectious causes not related to relapse. TRM at 100 days was 0%. At the end of follow-up (median 21 months), non-relapse mortality was 19%. Sequential chimerism studies of BM cells, performed 6 months after alloSCT and before the administration of DLI, showed sustained mixed chimerism with a median donor percentage of 68% (n ¼ 11 range, 1-99%). Five patients showed conversion into full-donor chimerism within 6 months after the administration of DLI, and maintained their full-donor chimerism status at the time of last assessment (see Table 2 ). In three patients low percentages of donor chimerism after the alloSCT and DLI were observed due to rapidly progressing disease.
Six months after alloSCT and before the administration of DLI one patient was in CR (8%), eight patients had persistent disease (perD, 67%) and three patients had progressive disease (PD, 25%). One patient (patient 3) was in CR at the time of alloSCT and remained in CR during follow-up of 25 months. In four out of eight patients with perD, the elimination of CLL cells in BM was observed after the administration of DLI, resulting in an ongoing CR. In one of these four patients, the CR was unconfirmed because of persistent abdominal lymphadenopathy (patient 5). Patient 1 had still perD 3 months after DLI. Patients 4 and 11 with perD were not evaluable for disease response because of too short follow-up after DLI and death, respectively. Patient 10 developed PD despite the administration of escalating doses of DLI. Three patients suffered from PD shortly after alloSCT. None of them showed any disease response upon the cellular adoptive therapy. Two of these patients (patients 2 and 8) received a second transplant from the original donor with a myeloablative conditioning. Patient 2 ultimately died from PD. At a median follow-up time of 21 months (range, 5-61 months), nine patients are alive. Kaplan-Meier estimated probabilities of overall survival (OS) and event-free survival (EFS) were 67 and 33% respectively, at 2 years ( Figure 1 ). For both T-cell-depleted and T-cell-repleted transplantation protocols comparable OS rates have been reported. Higher EFS rates are reported in two large series with T-cell-repleted transplantation protocols (52 and 67%); however at the cost of considerable morbidity due to acute and extensive chronic GvHD. [1] [2] [3] [4] To characterize allogeneic immune responses and the possible graft-versus-CLL activity, T cells from a patient successfully treated with DLI (patient 6), and T cells from a patient refractory to several applications of DLI after an initial partial response (patient 10) were studied. In both patients, the CLL was refractory to fludarabine and had unmutated IgV H genes. In patient 10, the CLL had unfavorable cytogenetics (11q-). As shown in Figure 2a , patient 6 converted into full-donor chimerism after the application of two doses of DLI and flow cytometric analysis of the BM remained negative for CLL cells. In contrast, patient 10 initially partially responded to DLI but despite five doses of DLI (maximum dose 1. Letters to the Editor grade I GvHD of the skin for which local corticosteroid ointment was applied.
As illustrated in Figure 2 , T cells isolated from PB of the two patients during clinical response, 6-7 weeks after the application of DLI, were stimulated with patient-derived primary CLL cells or CLL cells, modified into antigen-presenting cells (CLL-APC) using CD40 triggering and IL-4. 6 T cells responding to in vitro stimulation with the leukemia or the leukemic APC by the production of interferon-g (IFN-g) were sorted one cell per well and expanded. 7 In patient 6, the percentages of IFN-g-secreting T cells after 16 h of stimulation with primary CLL were 0.04% and with CLL-APC 0.22%. From patient 6, 23 proliferating clones out of 192 sorted T cells were obtained in response to primary CLL (plating efficiency 12%), and 3 of these clones exerted cytolytic activity against CLL-APC but not against primary CLL (data not shown). Using CLL-APC as stimulators, 148 T-cell clones were isolated out of 1346 sorted T cells, resulting in a plating efficiency of 11%. As illustrated in Figure 3a , 13 out of these 148 proliferating clones showed specific lysis of CLL-APC (46714%, mean7s.d.) and 8 of these cytotoxic T-cell (CTL) clones showed cytotoxic reactivity against primary CLL (24717%) in overnight 51 Cr assays. IFN-g was produced by all of these cytotoxic clones in response to CLL and CLL-APC (2557197 and 5467375 pg/ml, respectively, Figure 3b ), whereas no production of IFN-g was found by randomly tested non-CTL clones. None of the CTL clones produced IL-4. All clones were CD8 þ except for two CD4 þ clones (clones 6.28 and 6.96). Three CTL clones (clones 6.15, 6.70 and 6.85) recognized phytohemagglutinin (PHA) blasts of the patients (lysis 59, 66 and 23%, respectively), indicating that these clones were minor histocompatibility antigen (mHag)-specific. No reactivity with donor PHA blasts was observed. To further characterize the CTL clones obtained, blocking studies were performed. Cytolytic activity of three representative CD8 þ clones 6.15, 6.49 and 6.70 could be abrogated using the a-HLA class I monoclonal antibody (MoAb) (Figure 3c ), confirming HLA-restricted recognition. Additional experiments showed that a-HLA BC MoAb could block the recognition by clones 6.15 and 6.70, and not the cytotoxicity of clone 6.49 (Figure 3c) . A blocking study using a-HLA A2 MoAb showed HLA-A2 restricted recognition of clone 6.49 (data not shown). To analyze further and confirm the HLA-restricting molecule, clones 6.15, 6.49 and 6.70 were tested for reactivity against a panel of EBV-LCL from unrelated individuals that shared an HLA allele with the recipient. Clone 6.15 demonstrated HLA-B51-restricted recognition, clone 6.49 HLA-A2-restricted recognition and clone 6.70 exerted its reactivity in an HLA-B53-restricted way. The cytotoxicity of the CD4 þ clones 6.28 and 6.96 could be blocked by a-HLA class II MoAb (Figure 3d ). Cytolytic activity of clone 6.96 could be blocked by a-HLA DP MoAb (Figure 3d) .
In patient 10, T cells obtained 6-7 weeks after the first, and 6-7 weeks after the second application of DLI were stimulated for 16 h with primary CLL or CLL-APC in three independent experiments. The percentages of IFN-g-secreting T cells were 0.07-0.11% in response to primary CLL and 0.09-0.16% in response to CLL-APC. After single cell per well sorting of the viable IFN-g-secreting cells, no proliferating clones were obtained in response to primary CLL and a total of 13 proliferating T-cell clones were obtained using CLL-APC as Letters to the Editor stimulator cells. None of these T-cell clones, recognized CLLspecific and/or patient-specific targets nor did they produce any IL-4 or IFN-g upon stimulation (data not shown).
In summary, the experiments performed with the in vivo primed T cells from patient 6 showed that comparable percentages of proliferating T-cell clones were obtained in response to primary CLL and CLL-APC. However, the stimulation with CLL-APC resulted in a more efficient isolation of CTL clones reactive to primary CLL, suggesting that primary CLL as weak immunogenic APC has limited capacity to activate CLL-reactive T cells. For patient 10 suffering from PD despite the administration of several doses of DLI, no CLL-reactive CTL clones could be obtained in response to primary CLL or CLL-APC.
To analyze whether persistent CLL cells had the capacity to generally suppress the induction of T-cell responses, the presence and numbers of virus-specific T cells were studied using tetramer analysis after alloSCT and before and after DLI. In patient 6, 3.89% (mean of four time points; range 3.06-5.59%) of the CD8 þ T cells were CMV-specific and in patient 10, 1.56% (mean n ¼ 4; range 0.87-2.43%) of the T cells were EBVspecific (data not shown). The virus-specific T cells were of donor origin. These high numbers of virus-specific T cells in both patients illustrated that an adequate donor-derived T-cell response against virus-specific antigens had developed and that this immune response was not hampered by the presence of persistent CLL cells per se.
To investigate whether a precursor CLL-reactive T-cell repertoire was present in the transplant donor of patient 10 despite the absence of a persistent clinical response to DLI in the patient, a primary T-cell response against CLL-APC and primary CLL was generated. T cells derived from the donor were stimulated with CLL or CLL-APC. After 14 days of culture, the T cells were specifically restimulated and responding T cells were selected on the basis of their IFN-g production. Using CLL as stimulator cells, 67 proliferating clones could be tested for cytotoxicity resulting in one CD4
þ CTL clone with reactivity against CLL-APC (data not shown). After stimulation with CLL-APC, 129 proliferating clones were obtained, reflecting a high plating efficiency of 44%. Of these clones, 35 (34 CD8 þ and 1 CD4
þ clone) showed cytotoxicity against CLL-specific and/or patient-specific targets. As illustrated in Figure 4a , representative CD8 þ CTL clones and the CD4 þ CTL clone effectively lysed the primary CLL, the CLL-APC and PHA blasts from the patient and not donor PHA blasts in an overnight 51 Cr assays, indicating that the majority of these clones were mHag-specific. HLArestricted recognition was demonstrated by blocking experiments (Figure 4b) . Additional experiments demonstrated that several clones (for example, clones 10.6, 10.9 and 10.37) had the same HLA-restriction element. The cytolytic activity of these clones could be abrogated with a-HLA-A3 antibodies (Figure 4b ). Other clones (clones 10.107 and 10.131) exerted their activity in an HLA-B35-restricted way (data not shown). Thus, we demonstrated the feasibility to generate a CLL-reactive mHag-specific CTL response from the stem cell donor of patient 10, illustrating the presence of precursor leukemia T cells in the unprimed donor. The T-cell responses could only be induced against CLL-APC, indicating the limited APC function of the primary CLL, which may have underlaid the absence of the clinical response.
In conclusion, our post-DLI experiments demonstrated that in the patient suffering from progressive disease (patient 10) no leukemia-reactive T-cell responses could be isolated. In contrast, primary CLL-reactive T-cell responses could be induced from the unprimed donor only in response to CLL-APC but not to unmodified CLL. These results indicate that precursor CLL-reactive T cells were present in the DLI, but in vivo inadequately stimulated by the low immunogenic primary CLL resulting in T-cell tolerance towards primary CLL. The high numbers of donor virus-specific T cells in this patient illustrated that it is unlikely that CLL cells have the intrinsic capacity to suppress an adequate immune response per se. This patient suffered from CLL with unfavorable prognostic features. However, several reports have demonstrated that the adverse prognosis of unfavorable CLL may be overcome by alloSCT, indicating that aggressive chemotherapy refractory CLL can be susceptible to a GvL effect. 8 Patient 6 had a persistent CR after DLI. In the post-DLI experiments, leukemia-reactive mHagspecific CTL clones with different specificities could be isolated, but only in response to CLL-APC. These data suggest that the good clinical response after DLI in this patient is related to the presence of multiple CLL-reactive mHag-specific T cells. However, our data also illustrate that the primary CLL cells may not efficiently stimulate the proliferation of the mHagspecific CLL-reactive T cells, even after in vivo priming. We hypothesize that the GvL effect in this patient is largely mediated by donor T cells, showing alloreactivity against mHag expressed on residual recipient APC, or engrafted donor APC efficiently cross-presenting alloantigens expressed on CLL cells.
New cellular immunotherapeutic approaches necessary to improve specificity and efficacy of the GvL response may be the in vitro generation of CLL-reactive T-cell lines and clones from the donor using CLL-APC as stimulator cell. 7 The repetitive stimulation with CLL-APC may ultimately result in a relatively enrichment of leukemia-reactive T cells as compared to GvHDmediating T cells. Furthermore, by in vitro priming of CLLreactive donor T cells against CLL-APC T-cell anergy towards primary CLL may be minimized.
